ReviewJournal of pharmaceutical policy and practice2023

The reimbursement process in three national healthcare systems: variation in time to reimbursement of pembrolizumab for metastatic non-small cell lung cancer.

Sarah Sharman Moser et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.